{"id":"W2787959738","doi":"10.1111/dom.13257","title":"Alirocumab vs usual lipid‐lowering care as add‐on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM‐DYSLIPIDEMIA randomized trial","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Regeneron Pharmaceuticals; Sanofi","keywords":"Alirocumab; Ezetimibe; Medicine; Internal medicine; Dyslipidemia; PCSK9; Population; Type 2 diabetes; Fenofibrate; Gastroenterology; Endocrinology; Clinical endpoint; Statin; Randomized controlled trial; Cholesterol; Diabetes mellitus; Apolipoprotein B; Lipoprotein; Apolipoprotein A1; LDL receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001200318,0.001169952,0.002140717,0.0003198677,0.0003046769,0.0009703097,0.0005856002,0.001057452,0.004869598],"category_scores_gemma":[0.001643408,0.0004341926,0.00164588,0.0002730541,0.0005304605,0.0006508891,0.0004899767,0.001597585,0.0004499581],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005919086,"about_ca_system_score_gemma":0.0006426696,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001483719,"about_ca_topic_score_gemma":0.003164004,"domain_scores_codex":[0.9994592,0.0002921821,0.00004406766,0.00009425149,0.00003954511,0.00007069991],"domain_scores_gemma":[0.999513,0.0001146478,0.0001262192,0.00003481332,0.00003632251,0.000174982],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9858641,0.001874451,0.001186284,0.0005943649,0.001336119,0.00003122824,0.00002632813,0.0001536762,0.0007237409,0.00007713054,0.000457134,0.007675467],"study_design_scores_gemma":[0.9715152,0.02101071,0.004117123,0.00006959253,0.001814983,0.00004177143,0.00003005864,0.0005643907,0.0002071537,0.0001429596,0.0004742758,0.00001170061],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.98843,0.006237898,0.0002962461,0.0008071415,0.0005293416,0.0009922312,0.0006090905,0.00006095454,0.002037159],"genre_scores_gemma":[0.9912476,0.002447286,0.0008225237,0.001182875,0.0004104081,0.001244884,0.000686238,0.00001021995,0.001948064],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004869598,"threshold_uncertainty_score":0.01629049,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009826980854002007,"score_gpt":0.2588897558509697,"score_spread":0.2490627749969677,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}